Hemostemix Inc. is a regenerative medicine company focused on one mission: restoring blood flow where conventional medicine has failed. Our lead therapy, ACP-01 (VesCell), is an autologous angiogenic cell treatment derived from a patient’s own blood designed to grow new, lasting micro-vasculature in the body where that need is singled—those suffering from peripheral arterial disease, chronic limb-threatening ischemia, angina, cardiomyopathy, heart failure, and vascular dementia.